 
July 15, 2005
High Price of New Protease Provokes Protests
Monday, July 18, 2005—With some observers saying that the future of HIV-drug profits looks shaky, what’s a pharma to do? Charge more? Not if the AIDS Treatment Activist Coalition (ATAC) can help it: The group cried foul
when it learned that the newly approved protease inhibitor Aptivus
(tipranavir) was priced at $13,000 a year, making it the most expensive
PI ever. At press time, the drug’s maker, Boehringer-Ingelheim, hadn’t
yet officially responded to the ATAC attack.
[Go to top]
|
